BeStock  
Stocks › Biotechnology › BCAX

Bicara Therapeutics BCAX

US equityMarket cap rank #3530Biotechnology
$8.44 −$0.68 (-7.46%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.44 0.00%
Open$8.83
Prev close$9.12
Day range$8.43 – $9.14
Volume814.5K
Market cap$560.31M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$75.71M-86.1% YoY
Net profit-$71.25M-96.1% YoY
Diluted EPS-$1.04-55.2% YoY
Free cash flow-$56.79M-93.9% YoY
Operating cash flow-$56.13M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-21.0MDec '24$-36.8MMar '25$-27.4MJun '25$-36.3MSep '25$-37.4MDec '25$-56.2MMar '26$-55.4MJun '26$-71.2MSep '26

Diluted EPS by quarter

-0.39Dec '24-0.68Mar '25-0.50Jun '25-0.67Sep '25-0.68Dec '25-0.93Mar '26-0.82Jun '26-1.04Sep '26

Free cash flow by quarter

$-30.1MDec '24$-28.1MMar '25$-25.6MJun '25$-29.3MSep '25$-24.1MDec '25$-37.6MMar '26$-44.3MJun '26$-56.8MSep '26

Annual revenue

$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-54.2%
Return on assets-49.8%
Return on invested capital-56.6%
Current ratio8.81
Liabilities / assets11.1%
Cash & investments$442.35M
Total debt$0.00
Net cash (debt)$442.35M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $75.71M $59.95M $60.24M $155.60M $41.12M
Selling and Admin Expenses $19.24M $14.18M $12.74M $30.51M $8.13M
-General & Admin Expense $19.24M $14.18M $12.74M $30.51M $8.13M
Research & Development $56.48M $45.77M $47.50M $125.10M $32.99M
Operating Profit -$75.71M -$59.95M -$60.24M -$155.60M -$41.12M
Net Non-Operating Interest Income (Expense) $4.52M $4.58M $4.08M $17.87M $3.79M
Non-Operating Interest Income $4.52M $4.58M $4.08M $17.87M $3.79M
Pretax Profit -$71.20M -$55.38M -$56.16M -$137.73M -$37.33M
Tax $54,000.00 $61,000.00 $52,000.00 $217,000.00 $53,000.00
Net Profit -$71.25M -$55.44M -$56.21M -$137.95M -$37.39M
Profit from Continuing Operations -$71.25M -$55.44M -$56.21M -$137.95M -$37.39M
Net Income to Parent Company -$71.25M -$55.44M -$56.21M -$137.95M -$37.39M
Net Income to Common Stockholders -$71.25M -$55.44M -$56.21M -$137.95M -$37.39M
Basic EPS -$1.04 -$0.82 -$0.93 -$2.52 -$0.68
Diluted EPS -$1.04 -$0.82 -$0.93 -$2.52 -$0.68

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $460.64M $512.24M $553.60M $430.99M $430.99M
Total Current Assets $451.41M $503.82M $544.92M $422.05M $422.05M
Cash and Cash Equivalents & Short-Term Investments $442.35M $497.26M $539.75M $414.80M $414.80M
-Cash and Cash Equivalents $82.02M $96.60M $323.46M $96.69M $96.69M
-Short Term Investments $360.33M $400.66M $216.29M $318.12M $318.12M
Other Current Assets $9.06M $6.56M $5.16M $7.25M $7.25M
Total Non-Current Assets $9.23M $8.42M $8.68M $8.94M $8.94M
Net PPE $1.69M $1.51M $1.77M $2.03M $2.03M
-Gross PPE $1.69M $1.51M $1.77M $2.03M $2.03M
Other Non-Current Assets $7.54M $6.91M $6.91M $6.91M $6.91M
Total Liabilities $51.23M $43.48M $39.64M $29.54M $29.54M
Total Current Liabilities $51.23M $43.48M $39.34M $28.95M $28.95M
Payables $3.64M $8.46M $7.44M $7.79M $7.79M
-Accounts Payable $3.64M $8.46M $7.44M $7.79M $7.79M
Current Accrued Expenses $40.00M $29.80M $28.85M $15.00M $15.00M
Short-Term Debt and Capital Lease Obligation $880,000.00 $1.16M $1.14M $1.12M $1.12M
-Current Capital Lease Obligation $880,000.00 $1.16M $1.14M $1.12M $1.12M
Total Non-Current Liabilities $0.00 $0.00 $301,000.00 $593,000.00 $593,000.00
Long Term Debt and Capital Lease Obligation $0.00 $0.00 $301,000.00 $593,000.00 $593,000.00
-Long Term Capital Lease Obligation $0.00 $0.00 $301,000.00 $593,000.00 $593,000.00
Total Equity $409.41M $468.77M $513.96M $401.45M $401.45M
Stockholders' Equity $409.41M $468.77M $513.96M $401.45M $401.45M
Capital Stock $8,000.00 $8,000.00 $8,000.00 $7,000.00 $7,000.00
-Common Stock $8,000.00 $8,000.00 $8,000.00 $7,000.00 $7,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $953.13M $939.94M $929.37M $760.17M $760.17M
Retained Earnings -$541.86M -$470.61M -$415.18M -$358.97M -$358.97M
Gains/Losses Not Affecting Retained Earnings -$1.87M -$567,000.00 -$243,000.00 $243,000.00 $243,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$56.13M -$44.21M -$37.51M -$106.83M -$23.89M
Net cash flow from continuing operations -$56.13M -$44.21M -$37.51M -$106.83M -$23.89M
Net Income from Continuing Operations -$71.25M -$55.44M -$56.21M -$137.95M -$37.39M
Depreciation & Depletion & Amortization $60,000.00 $44,000.00 $44,000.00 $105,000.00 $43,000.00
Other Non-Cash Items $428,000.00 $277,000.00 $273,000.00 $895,000.00 $297,000.00
Change in Working Capital $4.62M $2.43M $12.19M $14.81M $8.44M
-Change in Prepaid Assets -$3.14M -$1.40M $2.09M $5.28M $839,000.00
-Change in Payables and Accrued Expense $8.04M $4.11M $10.37M $10.46M $7.90M
-Change in Other Current Liabilities -$283,000.00 -$277,000.00 -$270,000.00 -$932,000.00 -$292,000.00
Net cash flow from investing $38.34M -$184.99M $100.94M -$318.45M -$82.33M
Net Cash Flow from Continuing Investing Activities $38.34M -$184.99M $100.94M -$318.45M -$82.33M
Net PPE Purchase and Sale -$663,000.00 -$60,000.00 -$60,000.00 -$280,000.00 -$238,000.00
Net Investment Purchase and Sale $39.00M -$184.93M $101.00M -$318.17M -$82.09M
Financing Cash Flow $3.21M $2.33M $163.35M $32.26M $31.23M
Net Cash Flow from Continuing Financing Activities $3.21M $2.33M $163.35M $32.26M $31.23M
Net Common Stock Issuance $0.00 $0.00 $161.76M $29.50M $29.50M
Proceeds from Stock Option Exercised $3.21M $2.33M $1.58M $2.76M $1.73M
Ending Cash Balance $82.02M $96.60M $323.46M $96.69M $96.69M
Net Change in Cash -$14.58M -$226.86M $226.78M -$393.03M -$74.99M
Beginning Cash Balance $96.60M $323.46M $96.69M $489.71M $171.67M
Free Cash Flow -$56.79M -$44.27M -$37.57M -$107.11M -$24.12M

Discussion

No comments yet — be the first to weigh in on BCAX.

Sign in to join the discussion.

Scroll to Top